Momat Reno 50 ug / dose to 60 doses of nasal spray metered

The instruction for medical use of Momat Rino Torgovoye medicine a name Momat of Rino Mejdunarodnoye the unlicensed name Mometazon Lekarstvennaya a form the Spray nasal dosed of 50 mkg / a dose, 60 doses and 120 doses contains Structure of 1 g of drug active agent: a mometazona of furoate monohydrate of 0.517 mg (it is equivalent to a mometazon furoate) (0.500 mg), excipients: avitset RC-591 (cellulose microcrystalline, a karmelloza of sodium), glitserol, citric acid monohydrate, sodium citrate, polysorbate 80, a benzalkoniya chloride, water purified. The description Transparent, dense suspension from white till whitish color. Pharmacotherapeutic group of Antikongestanta and other nasal drugs. Nasal drugs. Corticosteroids. Mometazon. ATH R01AD09 code the Pharmacological Pharmacokinetics Bioavailability properties of a mometazon of furoate at use in the form of nasal spray very low (& lt, 0.1%), and it practically does not decide in blood plasma, even when using a sensitive method of definition on a threshold of sensitivity of 0.25 pg/ml. In vitro linking of a mometazon of furoate with proteins makes 98% - 99%, in the range of concentration from 5 to 500 ng/ml. Researches showed that mometazon furoate is metabolized on several metabolites. The main metabolites in plasma are not revealed. After an incubation of in vitro the minor metabolite 6β-гидрокси-mometazon furoate is revealed. In microsomes of a liver of the person the forming of a metabolite is regulated by R-450 3A4 cytochrome (CYP3A4). After intravenous administration the elimination half-life of a mometazon of furoate makes 5.8 hours of plasma. It is brought out of an organism in the form of metabolites generally with bile, and in insignificant degree with urine. Mometazon's pharmacodynamics furoate - a synthetic corticosteroid for topical administration with the significant anti-inflammatory action. Local anti-inflammatory action of a mometazon of furoate is shown in such doses at which there are no system effects. The mechanism of anti-inflammatory and antiallergenic action of a mometazon of furoate is connected with its ability to reduce discharge of mediators of allergic reactions. It is also powerful inhibitor of products Th2 of cytokines, IL-4 and IL-5. nasal Momat Rino spray shows anti-inflammatory activity at an early and late stage of allergic reaction. Indications - seasonal or year-round allergic rhinitis at adults and children are more senior than 6 years - prevention of allergic rhinitis of an average and heavy course (it is recommended in 2 - 4 weeks prior to the expected beginning of a season of blossoming) - nasal polyps and the related symptoms, including congestion of a nose and loss of sense of smell, at patients 18 years the Route of administration and doses For nasal use are more senior. Before the first use Momat Rino, nasal spray it is necessary to carry out its calibration by pressing of the portioning device of 10 times. After 'calibration' the stereotypic supply of medicinal substance at which to each pressing there is an emission about 100 mg of the suspension containing 50 mkg of a mometazon of furoate (one dose) is established. If nasal spray was not used within 14 days or longer, repeated calibration is necessary. Before each use it is necessary to stir up a spray bottle vigorously. Seasonal or year-round allergic rhinitis Adults (including elderly patients) and children of 12 years is also more senior: the usual recommended dose makes two injections (50 micrograms / a dose) in each nostril once a day (the general dose of 200 mkg). After achievement of medical effect for maintenance therapy it is reasonable to lower a dose to one injection in each nostril of 1 times a day (general dose of 100 mkg). If reduction of symptoms of a disease does not manage to be reached use of drug in the recommended therapeutic dose, the daily dose can be increased as much as possible up to 4 injections in each nostril of 1 times a day (general daily dose of 400 mkg). After reduction of symptoms of a disease the dose decline is recommended. Children aged from 6 up to 11 years: the recommended dose makes 1 injection (50 mkg) in each nostril of 1 times a day (general daily dose of 100 mkg). The beginning of clinical effect is noted within 12 hours after the first use of drug. Nasal polyps and the related symptoms, including congestion of a nose and loss of sense of smell Patients from 18 years (including for patients of advanced age) - the recommended dose makes 2 injections (50 mkg) in each nostril 2 times a day (the general daily dose - 400 mkg). After achievement of clinical effect it is recommended to reduce a dose to 2 injections in each nostril of 1 times a day (the general daily dose - 200 mkg). Side effects Often - irritation in the place of use, burning, an itching, sneezing, nasal bleeding - ulcer changes of a mucous membrane of a nose - a headache - pharyngitis Seldom - an asthma, a bronchospasm Very seldom - disturbance of sense of smell, taste - anaphylactic reactions, a Quincke's disease - perforation of a nasal partition of the Contraindication - hypersensitivity to drug components - nasal spray should not be used in the presence of not a treated local infection of a mucous membrane of a nose - because of the braking influence of steroids on healing of wounds, patients who underwent operations of a nose or an injury recently should not use nasal spray in an acute period Medicinal interactions When assigning Momat Rino, nasal spray along with loratadiny was not noted changes of plasma concentration of a loratadin or its main metabolite. Mometazona furoate did not decide in blood plasma on use of a sensitive method of definition with lower threshold of sensitivity of 50 pg/ml. Combination therapy by these drugs sick was transferred well. There are no data on interaction with other drugs. The special instructions Momat Rino should be applied with care or not to apply at patients with an active or latent tuberculosis infection of a respiratory path and also in not a treated fungal, bacterial infection, a system viral infection or in herpes simplex infection with damage of eyes. After 12-month treatment Momat Rino there were no symptoms of a mucosal atrophy of a nose, besides, a mometazona furoate contributed to normalization of a histologic picture of a mucous membrane of a nose. The patients applying Momat Rino within several months and longer have to have periodically examination regarding detection of possible changes of a mucous membrane of a nose. In case of development of a local fungal infection of a nose or a throat it is necessary to stop therapy by the drug Momat Rino or to carry out special treatment. The irritation of a mucous membrane of a nose and throat remaining for a long time can also be the indication to the drug treatment termination. Owing to the content in medicine a benzalkoniya of chloride there can be bronchospasm cases. At long-term treatment by the drug Momat Rino of signs of oppression of function gipotalamo - the hypophysial and adrenal system was not observed. Careful medical observation of the patients passing to treatment with nasal Momat Rino spray after long therapy by corticosteroids of systemic action is necessary. The termination of reception of corticosteroids of systemic action at such patients can result in insufficiency of function of bark of adrenal glands that can demand therapy resuming by system corticosteroids and uses of other corresponding treatment. During transition from treatment by corticosteroids of systemic action to the Momat Rino drug treatment some patients, along with simplification of nasal symptoms, can have symptoms of cancellation of corticosteroids (for example, joint and/or muscles pain, feeling of fatigue and a depression). Change of therapy can also reveal allergic diseases (such as allergic conjunctivitis, eczema, etc.) which developed earlier and masked therapy by corticosteroids of systemic action. The patients applying corticosteroids can potentially have reduced immune responsiveness and have to be warned about the increased risk of infection in case of contact with sick some infectious diseases (for example, chicken pox, measles) and also about need of medical consultation if such contact happened. It is necessary to warn patients about need of the immediate address to the doctor in case of signs or symptoms of a heavy bacterial infection, such as fervescence, severe unilateral pain in a face or a toothache, an orbital or periorbital swelling / puffiness, or aggravation of symptoms after preliminary improvement. There are separate messages about development of perforation of a nasal partition or increase in intraocular pressure after use of intranasal corticosteroids. Use for children Use of drug for children of younger age has to be carried out only under control of adults. It is regularly recommended to check growth of the children receiving long-term treatment by nasal corticosteroids. In case of identification of delay of growth it is necessary to consider the possibility of a dose decline of a nasal corticosteroid to the lowest dose at which effective control of symptoms is supported. In a similar case of the child it is necessary to consult at the pediatrician. Pregnancy and the period of a lactation Use of drug during pregnancy is not recommended. Use the period of a lactation is justified only when the expected advantage for mother exceeds any possible risk for the child. Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms In the recommended dose Momat Rino, nasal spray, does not affect ability to run transport or potentially dangerous mechanisms the Overdose Owing to small (≤ 0.1%) system bioavailability of the drug Momat Rino overdose is improbable. In case of overdose the observation of the patient with the subsequent use of drug in the recommended dose is necessary. The form of release and packing On 60 doses or 120 doses of drug place in bottles from polyethylene of high density, with the doser and a nozzle spray with a cap. On a bottle paste the label. On 1 bottle together with the instruction for medical use in the state and Russian languages place in a pack cardboard. To Store storage conditions in the place protected from light at a temperature from 15 °C to 30 °C. Not to freeze. To store out of children's reach! 2 years not to apply a period of storage after an expiration date. Prescription status According to the prescription the Name and the country of the organization - Glenmark Pharmasyyutikalz Ltd producer, India Viledzh Kishanpura, Buddy – Nalagarkh Road, Tekhsil Buddy, Distt. Solana (X. O)-173205 Name and the country of the owner of the registration certificate of Glenmark Pharmasyyutikalz Ltd, India
to Develop